logo

Cathay Industrial Biotech (CBIO)



Trade CBIO now with
  Date
  Headline
2/9/2018 7:32:56 AM Catalyst Biosciences Reports Positive Top-Line Data From Phase 1/2 Study Of Subcutaneous CB 2679d/ISU304
1/4/2018 8:08:26 AM Catalyst Biosciences Begins Phase 2/3 Trial Of Marzeptacog Alfa For Prophylaxis In Hemophilia A Or B With Inhibitors
12/22/2017 12:38:16 PM Catalyst Biosciences Announces Closing Of Public Offering Of Common Stock
12/18/2017 8:16:32 AM Aduro Biotech Announces Initiation Of Phase 1/2 Clinical Trial Of BION-1301
12/14/2017 8:32:44 AM Catalyst Biosciences Appoints Edward Williams To The Board
12/8/2017 11:29:08 AM B. Riley Initiates Catalyst Biosciences Inc. (CBIO) At Buy With $19 Price Target
11/28/2017 8:42:01 AM Catalyst Biosciences Appoints Arwa Shurrab VP Of Regulatory Affairs And Jamie Ellen Siegel Head Of Clinical Development
9/26/2017 8:03:44 AM Catalyst Biosciences Granted FDA ODD For Subcutaneous Recombinant Human Factor IX Variant For Hemophilia B
9/25/2017 8:08:38 AM Catalyst Biosciences Completes First Subcutaneous Dosing Cohort In Ongoing Hemophilia B Clinical Trial
9/11/2017 8:14:07 AM Catalyst Biosciences Unveils Issuance Of Asia Patents Covering Factor IX Hemophilia Program
8/3/2017 8:20:03 AM Catalyst Biosciences Q2 Loss Attributable To Common Stockholders $9.83 Mln Or $2.53/Shr
6/14/2017 8:02:37 AM Catalyst Biosciences And ISU Abxis Complete Dosing Of First Patient Cohort In Hemophilia B Clinical Trial